1. Home
  2. LOAN vs CLSD Comparison

LOAN vs CLSD Comparison

Compare LOAN & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LOAN
  • CLSD
  • Stock Information
  • Founded
  • LOAN 1989
  • CLSD 2011
  • Country
  • LOAN United States
  • CLSD United States
  • Employees
  • LOAN N/A
  • CLSD N/A
  • Industry
  • LOAN Real Estate Investment Trusts
  • CLSD Biotechnology: Pharmaceutical Preparations
  • Sector
  • LOAN Real Estate
  • CLSD Health Care
  • Exchange
  • LOAN Nasdaq
  • CLSD Nasdaq
  • Market Cap
  • LOAN 61.5M
  • CLSD 68.4M
  • IPO Year
  • LOAN 1999
  • CLSD 2016
  • Fundamental
  • Price
  • LOAN $5.39
  • CLSD $0.41
  • Analyst Decision
  • LOAN
  • CLSD Hold
  • Analyst Count
  • LOAN 0
  • CLSD 4
  • Target Price
  • LOAN N/A
  • CLSD $4.33
  • AVG Volume (30 Days)
  • LOAN 19.3K
  • CLSD 780.5K
  • Earning Date
  • LOAN 07-22-2025
  • CLSD 08-08-2025
  • Dividend Yield
  • LOAN 8.53%
  • CLSD N/A
  • EPS Growth
  • LOAN N/A
  • CLSD N/A
  • EPS
  • LOAN 0.48
  • CLSD N/A
  • Revenue
  • LOAN $7,300,469.00
  • CLSD $4,166,000.00
  • Revenue This Year
  • LOAN N/A
  • CLSD $78.37
  • Revenue Next Year
  • LOAN $4.47
  • CLSD $17.79
  • P/E Ratio
  • LOAN $11.23
  • CLSD N/A
  • Revenue Growth
  • LOAN N/A
  • CLSD N/A
  • 52 Week Low
  • LOAN $4.74
  • CLSD $0.29
  • 52 Week High
  • LOAN $6.05
  • CLSD $1.65
  • Technical
  • Relative Strength Index (RSI)
  • LOAN 47.19
  • CLSD 39.24
  • Support Level
  • LOAN $5.37
  • CLSD $0.39
  • Resistance Level
  • LOAN $5.55
  • CLSD $0.44
  • Average True Range (ATR)
  • LOAN 0.13
  • CLSD 0.04
  • MACD
  • LOAN -0.01
  • CLSD 0.01
  • Stochastic Oscillator
  • LOAN 32.43
  • CLSD 36.73

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About CLSD Clearside Biomedical Inc.

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Share on Social Networks: